高危或极高危前列腺癌根治性前列腺切除术后的肿瘤学与功能结局:现行NCCN指南的欧洲验证
回顾性分析1992至2016年接受根治性前列腺切除术的4041例患者,比较高危与极高危组的病理、功能和肿瘤学结局。极高危组不良病理特征更高,功能结局相似,5年和8年肿瘤学结局显著更差,验证了NCCN极高危分层的有效性。
要点
- 极高危组不良病理特征比例高于高危组。
- 两组1年控尿率和勃起功能率相似。
- 极高危组5年和8年肿瘤学结局显著劣于高危组。
核心结论
- 高危前列腺癌患者接受根治性前列腺切除术可获得较好的5年和8年转移无进展生存、前列腺癌特异性死亡无生存和总生存。
- 极高危组较高危组病理和肿瘤学结局显著更差,更常需要额外治疗。
- 这些观察验证了欧洲患者中高危与极高危分层的有效性。
- 极高危患者接受根治性前列腺切除术后功能结局并不比高危患者差。
研究设计与样本
- 回顾性分析1992年至2016年接受根治性前列腺切除术的4041例患者,分为高危组2672例和极高危组1369例。
- 采用Kaplan-Meier法以及多变量逻辑回归和Cox回归分析比较两组结局。
- 肿瘤学结局分析基于1992年至2011年接受手术的1835例患者亚组,中位随访58.8个月(IQR 36.5-84.6)。
主要发现
- 极高危组1369例较高危组2672例不良病理特征比例更高。
- 极高危组1年控尿率和勃起功能率分别为81.0%和43.6%,高危组分别为81.9%和45.2%(p=0.7和p=0.9)。
- 极高危组5年和8年生化复发无生存、转移无进展生存、前列腺癌特异性死亡无生存和总生存率均显著劣于高危组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We validated the current NCCN (National Comprehensive Cancer Network®) classification of very high risk patients, and compared the pathological, functional and oncologic outcomes between surgically treated high risk and very high risk patients. MATERIALS AND METHODS: We retrospectively analyzed 4,041 patients stratified into high risk or very high risk groups who underwent radical prostatectomy between 1992 and 2016. Kaplan-Meier as well as multivariable logistic and Cox regression analyses were used to compare outcomes between the groups. RESULTS: After radical prostatectomy the rate of adverse pathological features was higher in 1,369 very high risk vs 2,672 high risk cases. Functional outcomes were similar between the groups, with 1-year continence and potency rates of 81.0% and 43.6% in the very high risk compared to 81.9% and 45.2% in the high risk group, respectively (p = 0.7 and p = 0.9). In a subset of 1,835 patients who underwent radical prostatectomy between 1992 and 2011 (median followup 58.8 months, IQR 36.5-84.6), those with very high risk disease had significantly worse 5 and 8-year biochemical recurrence-free survival, metastatic progression-free survival, prostate cancer specific mortality-free survival and overall survival rates compared to those with high risk disease. CONCLUSIONS: Despite the relatively poor prognosis of patients with high risk prostate cancer, radical prostatectomy results in favorable 5 and 8-year metastatic progression-free survival, prostate cancer specific mortality-free survival and overall survival rates. Relative to high risk cases, their very high risk counterparts have significantly worse pathological and oncologic outcomes, and more frequently require additional therapies. These observations validate the stratification between high risk and very high risk in European patients with prostate cancer. Interestingly, very high risk patients treated with radical prostatectomy did not have a worse functional outcome than their high risk counterparts.
引用
- Pompe RS, Karakiewicz PI, Tian Z, et al. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. J Urol. 2017. PMID: 28216329. doi:10.1016/j.juro.2017.02.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。